She gets it. Listen to her question and Haluska's response at 36:15 on the conf. call. She asks a leading question about the data for T315i patients demonstrating much fewer AE's in less heavily pre-treated patients, suggesting front-line use will have more favorable safety profile.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.